Effectiveness of growth hormone therapy in children with Noonan syndrome

Purpose Recombinant human growth hormone (rhGH) has been used to improve growth in children with Noonan syndrome (NS). This study aimed to investigate the efficacy of rhGH therapy in Korean children with NS. Methods Seventeen prepubertal children (10 boys, 7 girls) with NS who received rhGH therapy...

Full description

Saved in:
Bibliographic Details
Main Authors: Eun mi Seok (Author), Hong Kyu Park (Author), Jung Gi Rho (Author), Change Dae Kum (Author), Hae Sang Lee (Author), Jin Soon Hwang (Author)
Format: Book
Published: Korean Society of Pediatric Endocrinology, 2020-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_4be3d2dc1ac14eefbbd3c2ca6cf9b4d9
042 |a dc 
100 1 0 |a Eun mi Seok  |e author 
700 1 0 |a Hong Kyu Park  |e author 
700 1 0 |a Jung Gi Rho  |e author 
700 1 0 |a Change Dae Kum  |e author 
700 1 0 |a Hae Sang Lee  |e author 
700 1 0 |a Jin Soon Hwang  |e author 
245 0 0 |a Effectiveness of growth hormone therapy in children with Noonan syndrome 
260 |b Korean Society of Pediatric Endocrinology,   |c 2020-07-01T00:00:00Z. 
500 |a 2287-1012 
500 |a 2287-1292 
500 |a 10.6065/apem.1938154.077 
520 |a Purpose Recombinant human growth hormone (rhGH) has been used to improve growth in children with Noonan syndrome (NS). This study aimed to investigate the efficacy of rhGH therapy in Korean children with NS. Methods Seventeen prepubertal children (10 boys, 7 girls) with NS who received rhGH therapy for at least 3 years between 2008 and 2017 were included. To compare the response, age- and sex-matched children with GH deficiency (GHD; n=31) were included. Height and growth velocity before and during treatment were analyzed. Results The mean age of NS patients was 6.34±2.32 years. After treatment, the height standard deviation score (SDS) increased from -2.93±0.81 to -1.51±1.00 in patients with NS and from -2.45±0.42 to -1.09±0.47 in patients with GHD. There were no significant differences in growth velocity or change in height SDS between patients with NS and GHD. Growth velocity in the first year of treatment was higher in patients with PTPN11 mutations than those without PTPN11 mutations, but the change in height SDS was not significantly different between those 2 groups. Conclusions rhGH therapy can increase linear growth in prepubertal children with NS. The growth response between patients with NS and patients with GHD was not significantly different. Furthermore, we observed that lower doses of growth hormone have a similar effect on height compared to previous studies in patients with NS. Our study indicates that rhGH treatment is useful for growth promotion. 
546 |a EN 
690 |a noonan syndrome 
690 |a growth hormone 
690 |a efficacy 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Annals of Pediatric Endocrinology & Metabolism, Vol 25, Iss 3, Pp 182-186 (2020) 
787 0 |n http://e-apem.org/upload/pdf/apem-1938154-077.pdf 
787 0 |n https://doaj.org/toc/2287-1012 
787 0 |n https://doaj.org/toc/2287-1292 
856 4 1 |u https://doaj.org/article/4be3d2dc1ac14eefbbd3c2ca6cf9b4d9  |z Connect to this object online.